Alvotech SA has announced the acquisition of Xbrane Biopharma AB's R&D operations located at the Karolinska life-science hub in Sweden. This strategic move is part of Alvotech's plans to expand its research and development capabilities and to solidify its presence in the Swedish life-science sector. The transaction has received approval from Xbrane's shareholders and necessary foreign direct investment authorities, with the closing expected in early June 2025. This acquisition will integrate Xbrane's workforce of experienced biosimilar developers into Alvotech, enhancing the company's scientific and innovation capabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001097207-en) on May 16, 2025, and is solely responsible for the information contained therein.